Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0YHA5 | ISIN: US23283M1018 | Ticker-Symbol: 296
Stuttgart
31.03.25
08:17 Uhr
0,200 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CYTODYN INC Chart 1 Jahr
5-Tage-Chart
CYTODYN INC 5-Tage-Chart

Aktuelle News zur CYTODYN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.03.CytoDyn Inc.: March 2025 Letter to Shareholders915VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. ("CytoDyn" or the "Company"). On February 24...
► Artikel lesen
24.02.CytoDyn Inc.: CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab278VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
CYTODYN Aktie jetzt für 0€ handeln
06.02.CytoDyn Inc.: CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories231VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
14.01.CytoDyn Inc. - 10-Q, Quarterly Report20
17.12.24CytoDyn Inc.: December 2024 Letter to Shareholders303VANCOUVER, Washington, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, As I look back on 2024, during which CytoDyn Inc. ("CytoDyn" or the "Company") achieved multiple crucial milestones...
► Artikel lesen
22.11.24CytoDyn Inc. - 8-K, Current Report-
04.11.24CytoDyn Inc.: CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial236VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
30.10.24CytoDyn Inc.: CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories3
15.10.24CytoDyn Inc. - 10-Q, Quarterly Report3
07.10.24CytoDyn Inc.: CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques6
04.10.24CytoDyn Inc.: CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial273VANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
09.09.24CytoDyn Inc.: September 2024 Letter to Shareholders306VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, It continues to be a transformative year for CytoDyn Inc. ("CytoDyn" or the "Company"). A year in which we have made significant...
► Artikel lesen
03.09.24Biotech-Favorit im September: Ocugen, Novavax, Clinuvel, Cytodyn1.901Immer mehr Profis erwarten eine neue Biotech-Hausse und positionieren sich für eine lange Rallye im Sektor. Cleveres Stockpicking ist jetzt entscheidend. Der anlaufende Monat September, ein historisch...
► Artikel lesen
12.08.24CytoDyn Inc.: CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer204VANCOUVER, Washington, Aug. 12, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
► Artikel lesen
16.05.24CytoDyn Inc.: May 2024 Letter to Shareholders335VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, I write today to provide an update on CytoDyn Inc. ("CytoDyn" or "Company"), as we approach the end of our 2024 fiscal...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2